A Study of LY2140023 in Patients With Schizophrenia

Summary

The purpose of this study is to determine whether at least 1 dose level of LY2140023 given to acutely ill patients with schizophrenia will demonstrate significantly greater efficacy as compared to placebo.

Timeline

Start

2011-03

Primary completion

2012-09

Completion

2012-09

Outcome

Missed primary endpoint

Stopped: “The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population.”

registry 80 mg LY2140023, BID vs Placebo; p = 0.994; LS mean difference 4.1 (95% CI -0.5 to 8.8) NCT01307800 ↗

Publications

• Kinon BJ, Millen BA, Zhang L, McKinzie DL. Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia. Biol Psychiatry. 2015 Dec 1;78(11):754-62. doi: 10.1016/j.biopsych.2015.03.016. Epub 2015 Mar 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY2140023	Unknown	10 mg	Oral
Subject	LY2140023	Unknown	40 mg	Oral
Subject	LY2140023	Unknown	80 mg	Oral

Indications